Candel Therapeutics (CADL) Stock Overview
A clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CADL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Candel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.65 |
| 52 Week High | US$13.68 |
| 52 Week Low | US$4.25 |
| Beta | -0.92 |
| 1 Month Change | 26.12% |
| 3 Month Change | 4.44% |
| 1 Year Change | -34.91% |
| 3 Year Change | 183.92% |
| 5 Year Change | n/a |
| Change since IPO | -19.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CADL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.1% | -2.6% | -1.4% |
| 1Y | -34.9% | 25.0% | 16.0% |
Return vs Industry: CADL underperformed the US Biotechs industry which returned 25.4% over the past year.
Return vs Market: CADL underperformed the US Market which returned 16.9% over the past year.
Price Volatility
| CADL volatility | |
|---|---|
| CADL Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CADL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CADL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 38 | Paul-Peter Tak | www.candeltx.com |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma.
Candel Therapeutics, Inc. Fundamentals Summary
| CADL fundamental statistics | |
|---|---|
| Market cap | US$313.47m |
| Earnings (TTM) | -US$22.76m |
| Revenue (TTM) | n/a |
Is CADL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CADL income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$23.07m |
| Gross Profit | -US$23.07m |
| Other Expenses | -US$315.00k |
| Earnings | -US$22.76m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.5% |
How did CADL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 10:00 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Candel Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Evan Seigerman | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |